ARCT (Arcturus Therapeutics Holdings) Institutional Ownership: 92.81% (As of Jul. 09, 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
50 GF Score
Price $7.16
GF Value $4.09
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Institutional Ownership?

Arcturus Therapeutics Holdings ARCT -1.78% 50 Institutional Ownership is 92.81% as of Jul. 09, 2026. GuruFocus rates ARCT with a GF Score™ of 50/100 and a GF Value™ of $4.09 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arcturus Therapeutics Holdings's institutional ownership is 92.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arcturus Therapeutics Holdings's Insider Ownership is 7.82%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arcturus Therapeutics Holdings's Float Percentage Of Total Shares Outstanding is 80.40%.

Arcturus Therapeutics Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings Institutional Ownership Chart

Arcturus Therapeutics Holdings Historical Data

The historical data trend for Arcturus Therapeutics Holdings can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 88.03 91.43 86.92 77.60 75.23 75.59 77.08 76.84 75.71 76.75
ARCT
50GF Score
Arcturus Therapeutics Holdings Inc ARCT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 92.81% mean?
Arcturus Therapeutics Holdings (ARCT) has a Institutional Ownership of 92.81% as of Jul. 09, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arcturus Therapeutics Holdings and its competitors.
Is Arcturus Therapeutics Holdings' Institutional Ownership too high?
Arcturus Therapeutics Holdings' current Institutional Ownership is 92.81%. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Institutional Ownership compare to MDWD and UNCY?
Arcturus Therapeutics Holdings' Institutional Ownership of 92.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current Institutional Ownership is 92.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.09, compared to a current price of $7.16 — trading 75.1% above its estimated fair value. The current Institutional Ownership is 92.81%. Arcturus Therapeutics Holdings' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Institutional Ownership is 92.81% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $7.16 is trading 75.1% above its estimated GF Value™ of $4.09. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Institutional Ownership: 92.81%
  • GF Value™: $4.09 vs. price of $7.16 (75.1% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
50GF Score

Get the complete analysis for ARCT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.16
Price
$4.09
GF Value